Bristol-myers Squibb Compnay

F. Hoffmann-la Roche Ag

Bristol-myers Squibb Pharma Company

Roche Innovation Center Copenhagen A/s

Stephen E Mercer

Richard Eric Olson

Prasad V Chaturvedula

Peter Hagedorn

Haiquan Fang

Marianne Lerbech Jensen

Niels Fisker Nielsen

Angela Marie Cacace

Anja Mølhart Høg

Jeffrey M Brown

Thomas P Maduskuie, Jr

Gene Michael Dubowchik

Xiaojun Han

Dong Li

John E Macor

Chu-Biao Xue

Jingwu Duan

Guanglin Luo

Upender Velaparthi

Robert G Gentles

Min Ding

Kenneth M Boy

Xiaofan Zheng

Ivar M McDonald

Graham S Poindexter

Scott W Martin

Louis Stanley Chupak

Andrew P Degnan

Yazhong Huang

Ivar M Mcdonald

Michael Wichroski

Xiaoliang Zhou

Brian R Anderson

Anja Mølhart HØG

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Naphthyridinone compounds useful as T cell activators

The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.

Methods of selecting therapeutic molecules

The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Tau antisense oligomers and uses thereof

The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

CAMK2D antisense oligonucleotides and uses thereof

The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.

Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Therapeutic agents for the treatment of migraine

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. 

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors 

The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R, R, R, R, Z, U, X, Y, Z, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&#x3b1; converting enzyme (TACE), or a combination thereof.

Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-&#x3b1; converting enzyme

Lactam metalloprotease inhibitors

Growing community of inventors

Middletown, CT, United States of America

Stephen E Mercer